The Community Blood Center and HSHS Wisconsin Announce Sole Provider Partnership for Blood and Blood Components
CBC to provide all blood products to the six HSHS hospitals in Wisconsin
The Community Blood Center (CBC) and Hospital Sisters Health System (HSHS) Wisconsin jointly announce a new partnership, where CBC will provide all blood and blood components transfused to patients at the six HSHS hospitals in Wisconsin. The partnership formally begins July 1, 2020.
Select this link for details.
Tests help identify potential convalescent plasma donors
SAN ANTONIO, Texas – QualTex Laboratories
is up and running with two assays to detect the presence of COVID-19 antibodies
in the bloodstream.
QualTex Laboratories, a subsidiary of
nonprofit BioBridge Global, has been performing the SARS-CoV-2 IgG Antibody
ELISA assay since April. A second assay, the Abbott Laboratories Architect
Antibody assay, went into full-scale production for a QualTex customer on June
“These two assays are part of our
continuing commitment to public health,” said Ward Carter, Chief Operating
Officer of QualTex Laboratories. “They give blood centers the information to
potentially save lives during the COVID-19 pandemic by helping to identify
potential COVID-19 convalescent plasma donors.”
- The Abbott assay checks blood samples for
the presence of antibodies to SARS-CoV-2. It is a high-throughput test suitable
for clinical laboratory use. Unlike current point-of-care tests, it has a high
accuracy rate: 99.4%.
- The SARS-CoV-2 IgG Antibody ELISA assay
tests for the concentration of antibodies to SARS-CoV-2. It provides titer
result detection of the IgG antibody anti-RBD, which is a portion of the
receptor-binding domain found on human coronavirus spike proteins. This assay is
not for diagnostic use.
Both tests can be used in the process of
identifying potential convalescent plasma donors. The Abbott assay determines if
a blood donor may have been exposed to the virus that causes COVID-19. The
SARS-CoV-2 IgG Antibody ELISA assay determines if donors have high enough level
of antibodies in their plasma to have an impact when their donated plasma is
transfused into seriously ill patients.
About QualTex Laboratories: QualTex Laboratories provides state-of-the-art biologic testing services on whole blood, plasma and human cells, tissue, and cellular- and tissue-based products for biotechnology and biopharmaceutical customers. It is one of the nation’s largest nonprofit testing laboratories with automation systems and has locations in Texas and Georgia. The center is a subsidiary of BioBridge Global, a nonprofit organization comprising services for regenerative medicine and research to help patients in South Texas, the United States and worldwide. Visit us at QualTexlabs.org.
About BioBridge Global: BioBridge Global (BBG) is a San Antonio, Texas-based 501(c)(3) nonprofit corporation that offers diverse services through its subsidiaries – the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure and The Blood & Tissue Center Foundation. BBG provides products and services in blood resource management, cellular therapy, donated umbilical cord blood and human tissue as well as testing of blood, plasma and tissue products for clients in the United States and worldwide. BBG is committed to saving and enhancing lives through the healing power of human cells and tissue. It enables advances in the field of regenerative medicine by providing access to human cells and tissue, testing services and biomanufacturing and clinical trials support. Learn more at BioBridgeGlobal.org.
San Diego Blood Bank adds solar + storage system to power electric blood mobile fleet
Enel X, the Enel Group’s advanced energy services business line, continues to grow its energy storage business in California, signing an agreement to manage a battery storage system as part of a solar + storage project at the San Diego Blood Bank. By combining onsite solar generation with a battery storage system, the Blood Bank will be able to self-generate, store and consume electricity, providing the facility with cost savings, while also reducing its environmental footprint. READ MORE
Red Cross Warns of a ‘Staggering’ Drop in Blood Supplies – The New York Times
Hospitals have resumed elective surgeries and many Americans are venturing out of their homes again, but the rate of donations has yet to bounce back. READ MORE
Duke Health, WakeMed and UNC Health are among hospital systems nationwide that are using plasma from survivors of COVID-19 to treat people who are still struggling with the illness.
And as demand for the so-called convalescent plasma grows, UNC Health has begun collecting donations from survivors, and WakeMed may soon do the same. READ MORE
CHERAW, South Carolina) — McLeod Health physicians and clinical staff are testing the effectiveness and outcomes of convalescent blood plasma to treat critically ill Covid-19 patients.
The Infectious Diseases and Critical Care teams at McLeod Health are participating in this trial led and developed by the United States government and Mayo Clinic. This treatment, developed from the blood plasma of fully recovered COVID-19 patients, is given to hospitalized patients with severe cases of COVID-19. READ MORE
GREENVILLE, SC (FOX Carolina) The Blood Connection has been working with patients who have recovered from the coronavirus, participating in a new program that focuses on using convalescent plasma to help treat those still fighting. READ MORE
WATERLOO — As the two major hospital systems in Black Hawk County find themselves on the front lines of the coronavirus pandemic, they’re at the forefront of finding a possible treatment for the deadly respiratory illness. READ MORE
DES MOINES, Iowa — The first patient in Iowa to receive a convalescent plasma donation to treat COVID-19 was released from the hospital last week.
According to a Facebook post from UnityPoint Health, Lance was released from Iowa Methodist Medical Center last week. He was able to spend the weekend with his family and is doing well. READ MORE
OKLAHOMA CITY (KFOR) – The Oklahoma Blood Institute has collected over 210 units of COVID-19 convalescent plasma (CCP) for innovative treatment of coronavirus patients.
The plasma was collected from 76 donors, according to an Oklahoma Blood Institute news release. READ MORE